pubmed-article:18096565 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:18096565 | lifeskim:mentions | umls-concept:C0013216 | lld:lifeskim |
pubmed-article:18096565 | lifeskim:mentions | umls-concept:C0684249 | lld:lifeskim |
pubmed-article:18096565 | lifeskim:mentions | umls-concept:C0007131 | lld:lifeskim |
pubmed-article:18096565 | lifeskim:mentions | umls-concept:C1122962 | lld:lifeskim |
pubmed-article:18096565 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
pubmed-article:18096565 | lifeskim:mentions | umls-concept:C1708063 | lld:lifeskim |
pubmed-article:18096565 | lifeskim:mentions | umls-concept:C0442711 | lld:lifeskim |
pubmed-article:18096565 | lifeskim:mentions | umls-concept:C0332283 | lld:lifeskim |
pubmed-article:18096565 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
pubmed-article:18096565 | pubmed:issue | 4 | lld:pubmed |
pubmed-article:18096565 | pubmed:dateCreated | 2008-3-26 | lld:pubmed |
pubmed-article:18096565 | pubmed:abstractText | Gefitinib is active in patients with pretreated non-small-cell lung cancer (NSCLC). We evaluated the activity and toxicity of gefitinib first-line treatment in advanced NSCLC followed by chemotherapy at disease progression. | lld:pubmed |
pubmed-article:18096565 | pubmed:language | eng | lld:pubmed |
pubmed-article:18096565 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18096565 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:18096565 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18096565 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18096565 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18096565 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18096565 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18096565 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18096565 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18096565 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18096565 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18096565 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18096565 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18096565 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:18096565 | pubmed:month | Apr | lld:pubmed |
pubmed-article:18096565 | pubmed:issn | 1569-8041 | lld:pubmed |
pubmed-article:18096565 | pubmed:author | pubmed-author:MayerMM | lld:pubmed |
pubmed-article:18096565 | pubmed:author | pubmed-author:MackKK | lld:pubmed |
pubmed-article:18096565 | pubmed:author | pubmed-author:WidmerLL | lld:pubmed |
pubmed-article:18096565 | pubmed:author | pubmed-author:RibiKK | lld:pubmed |
pubmed-article:18096565 | pubmed:author | pubmed-author:RauchDD | lld:pubmed |
pubmed-article:18096565 | pubmed:author | pubmed-author:StahelRR | lld:pubmed |
pubmed-article:18096565 | pubmed:author | pubmed-author:PlessMM | lld:pubmed |
pubmed-article:18096565 | pubmed:author | pubmed-author:StuppRR | lld:pubmed |
pubmed-article:18096565 | pubmed:author | pubmed-author:TapieGG | lld:pubmed |
pubmed-article:18096565 | pubmed:author | pubmed-author:BetticherD... | lld:pubmed |
pubmed-article:18096565 | pubmed:author | pubmed-author:JostLL | lld:pubmed |
pubmed-article:18096565 | pubmed:author | pubmed-author:BubendorfLL | lld:pubmed |
pubmed-article:18096565 | pubmed:author | pubmed-author:LerchSS | lld:pubmed |
pubmed-article:18096565 | pubmed:author | pubmed-author:D'AddarioGG | lld:pubmed |
pubmed-article:18096565 | pubmed:author | pubmed-author:BihlMM | lld:pubmed |
pubmed-article:18096565 | pubmed:issnType | Electronic | lld:pubmed |
pubmed-article:18096565 | pubmed:volume | 19 | lld:pubmed |
pubmed-article:18096565 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:18096565 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:18096565 | pubmed:pagination | 739-45 | lld:pubmed |
pubmed-article:18096565 | pubmed:dateRevised | 2010-11-18 | lld:pubmed |
pubmed-article:18096565 | pubmed:meshHeading | pubmed-meshheading:18096565... | lld:pubmed |
pubmed-article:18096565 | pubmed:meshHeading | pubmed-meshheading:18096565... | lld:pubmed |
pubmed-article:18096565 | pubmed:meshHeading | pubmed-meshheading:18096565... | lld:pubmed |
pubmed-article:18096565 | pubmed:meshHeading | pubmed-meshheading:18096565... | lld:pubmed |
pubmed-article:18096565 | pubmed:meshHeading | pubmed-meshheading:18096565... | lld:pubmed |
pubmed-article:18096565 | pubmed:meshHeading | pubmed-meshheading:18096565... | lld:pubmed |
pubmed-article:18096565 | pubmed:meshHeading | pubmed-meshheading:18096565... | lld:pubmed |
pubmed-article:18096565 | pubmed:meshHeading | pubmed-meshheading:18096565... | lld:pubmed |
pubmed-article:18096565 | pubmed:meshHeading | pubmed-meshheading:18096565... | lld:pubmed |
pubmed-article:18096565 | pubmed:meshHeading | pubmed-meshheading:18096565... | lld:pubmed |
pubmed-article:18096565 | pubmed:meshHeading | pubmed-meshheading:18096565... | lld:pubmed |
pubmed-article:18096565 | pubmed:meshHeading | pubmed-meshheading:18096565... | lld:pubmed |
pubmed-article:18096565 | pubmed:meshHeading | pubmed-meshheading:18096565... | lld:pubmed |
pubmed-article:18096565 | pubmed:meshHeading | pubmed-meshheading:18096565... | lld:pubmed |
pubmed-article:18096565 | pubmed:meshHeading | pubmed-meshheading:18096565... | lld:pubmed |
pubmed-article:18096565 | pubmed:meshHeading | pubmed-meshheading:18096565... | lld:pubmed |
pubmed-article:18096565 | pubmed:meshHeading | pubmed-meshheading:18096565... | lld:pubmed |
pubmed-article:18096565 | pubmed:meshHeading | pubmed-meshheading:18096565... | lld:pubmed |
pubmed-article:18096565 | pubmed:meshHeading | pubmed-meshheading:18096565... | lld:pubmed |
pubmed-article:18096565 | pubmed:meshHeading | pubmed-meshheading:18096565... | lld:pubmed |
pubmed-article:18096565 | pubmed:meshHeading | pubmed-meshheading:18096565... | lld:pubmed |
pubmed-article:18096565 | pubmed:meshHeading | pubmed-meshheading:18096565... | lld:pubmed |
pubmed-article:18096565 | pubmed:meshHeading | pubmed-meshheading:18096565... | lld:pubmed |
pubmed-article:18096565 | pubmed:meshHeading | pubmed-meshheading:18096565... | lld:pubmed |
pubmed-article:18096565 | pubmed:meshHeading | pubmed-meshheading:18096565... | lld:pubmed |
pubmed-article:18096565 | pubmed:meshHeading | pubmed-meshheading:18096565... | lld:pubmed |
pubmed-article:18096565 | pubmed:meshHeading | pubmed-meshheading:18096565... | lld:pubmed |
pubmed-article:18096565 | pubmed:meshHeading | pubmed-meshheading:18096565... | lld:pubmed |
pubmed-article:18096565 | pubmed:meshHeading | pubmed-meshheading:18096565... | lld:pubmed |
pubmed-article:18096565 | pubmed:meshHeading | pubmed-meshheading:18096565... | lld:pubmed |
pubmed-article:18096565 | pubmed:meshHeading | pubmed-meshheading:18096565... | lld:pubmed |
pubmed-article:18096565 | pubmed:meshHeading | pubmed-meshheading:18096565... | lld:pubmed |
pubmed-article:18096565 | pubmed:year | 2008 | lld:pubmed |
pubmed-article:18096565 | pubmed:articleTitle | Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03. | lld:pubmed |
pubmed-article:18096565 | pubmed:affiliation | Department of Oncology, Kantonsspital St.Gallen, St. Gallen, Switzerland. g.daddario@hin.ch | lld:pubmed |
pubmed-article:18096565 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:18096565 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
pubmed-article:18096565 | pubmed:publicationType | Multicenter Study | lld:pubmed |
pubmed-article:18096565 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18096565 | lld:pubmed |